Thomas T DeLeon1, Marcela A Salomao2, Bashar A Aqel3, Mohamad B Sonbol1, Raquel T Yokoda1, Ahmad H Ali3, Adyr A Moss4, Amit K Mathur4, David M Chascsa3, Jorge Rakela3, Alan H Bryce1, Mitesh J Borad1,5,6. 1. Division of Hematology & Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ, USA. 2. Division of Anatomic Pathology & Laboratory Medicine, Department of Pathology, Mayo Clinic, Scottsdale, AZ, USA. 3. Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Scottsdale, AZ, USA. 4. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Scottsdale, AZ, USA. 5. Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. 6. Mayo Clinic Cancer Center, Phoenix, AZ, USA.
Abstract
BACKGROUND: Patients with solid organ transplants (SOTs) have been excluded from programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor clinical trials due to concern for allograft rejection. The use of immune checkpoint inhibitor therapy remains controversial in transplant patients. METHODS: A retrospective pilot evaluation was conducted to assess the safety and efficacy of PD-1 inhibitors in patients with liver transplantation (LT). The primary endpoint was the rate of allograft rejection. Secondary endpoints included overall response rate (ORR), progression free survival (PFS) and overall survival (OS). Translational objectives included evaluation of tumor PD-L1, tumor infiltrating lymphocytes (TILs) and allograft PD-L1 expression. RESULTS: Seven metastatic cancer patients with a history of LT who received PD-1 inhibitor therapy were included [hepatocellular carcinoma (HCC), n=5; melanoma, n=2]. Rejection was observed in 2 of 7 patients. When rejection occurs it appears to be an early event with a median time to rejection of 24 days in our cohort. One patient achieved a complete response (CR), 3 patients had progressive disease (PD) and 3 patients discontinued therapy prior to restaging assessments. Two of five patients with available tissue had PD-L1 expression in the allograft and both developed rejection. One of five evaluable patients had abundant TILs. Two of five evaluable patients had PD-L1 tumor staining. The single patient with both abundant TILs and PD-L1 staining obtained a response. The median OS and PFS were 1.1 (0.3-21.1) and 1.8 (0.7-21.1) months, respectively. CONCLUSIONS: In this pilot evaluation both preliminary efficacy (1 of 4) and allograft rejection (2 of 7) were exhibited in evaluable patients. Larger, prospective trials are needed to elucidate optimal patient selection.
BACKGROUND: Patients with solid organ transplants (SOTs) have been excluded from programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor clinical trials due to concern for allograft rejection. The use of immune checkpoint inhibitor therapy remains controversial in transplant patients. METHODS: A retrospective pilot evaluation was conducted to assess the safety and efficacy of PD-1 inhibitors in patients with liver transplantation (LT). The primary endpoint was the rate of allograft rejection. Secondary endpoints included overall response rate (ORR), progression free survival (PFS) and overall survival (OS). Translational objectives included evaluation of tumor PD-L1, tumor infiltrating lymphocytes (TILs) and allograft PD-L1 expression. RESULTS: Seven metastatic cancer patients with a history of LT who received PD-1 inhibitor therapy were included [hepatocellular carcinoma (HCC), n=5; melanoma, n=2]. Rejection was observed in 2 of 7 patients. When rejection occurs it appears to be an early event with a median time to rejection of 24 days in our cohort. One patient achieved a complete response (CR), 3 patients had progressive disease (PD) and 3 patients discontinued therapy prior to restaging assessments. Two of five patients with available tissue had PD-L1 expression in the allograft and both developed rejection. One of five evaluable patients had abundant TILs. Two of five evaluable patients had PD-L1 tumor staining. The single patient with both abundant TILs and PD-L1 staining obtained a response. The median OS and PFS were 1.1 (0.3-21.1) and 1.8 (0.7-21.1) months, respectively. CONCLUSIONS: In this pilot evaluation both preliminary efficacy (1 of 4) and allograft rejection (2 of 7) were exhibited in evaluable patients. Larger, prospective trials are needed to elucidate optimal patient selection.
Authors: Engin Ozkaynak; Liqing Wang; Andrew Goodearl; Kevin McDonald; Shixin Qin; Theresa O'Keefe; Thao Duong; Tammy Smith; Jose-Carlos Gutierrez-Ramos; James B Rottman; Anthony J Coyle; Wayne W Hancock Journal: J Immunol Date: 2002-12-01 Impact factor: 5.422
Authors: Katsunori Tanaka; Monica J Albin; Xueli Yuan; Kazuhiro Yamaura; Antje Habicht; Takaya Murayama; Martin Grimm; Ana Maria Waaga; Takuya Ueno; Robert F Padera; Hideo Yagita; Miyuki Azuma; Tahiro Shin; Bruce R Blazar; David M Rothstein; Mohamed H Sayegh; Nader Najafian Journal: J Immunol Date: 2007-10-15 Impact factor: 5.422
Authors: L V Riella; T Watanabe; P T Sage; J Yang; M Yeung; J Azzi; V Vanguri; A Chandraker; A H Sharpe; M H Sayegh; N Najafian Journal: Am J Transplant Date: 2011-03-14 Impact factor: 8.086
Authors: Astrid Starke; Maja T Lindenmeyer; Stephan Segerer; Matthias A Neusser; Barbara Rüsi; Daniel M Schmid; Clemens D Cohen; Rudolf P Wüthrich; Thomas Fehr; Ying Waeckerle-Men Journal: Kidney Int Date: 2010-04-14 Impact factor: 10.612
Authors: Rita E Morales; Alexander N Shoushtari; Michelle M Walsh; Priya Grewal; Evan J Lipson; Richard D Carvajal Journal: J Immunother Cancer Date: 2015-06-16 Impact factor: 13.751
Authors: Ioannis A Ziogas; Alexandros P Evangeliou; Lipika Goyal; Georgios Tsoulfas; Dimitrios Giannis; Muhammad H Hayat; Konstantinos S Mylonas; Samer Tohme; David A Geller; Nahel Elias Journal: Oncologist Date: 2021-01-02
Authors: Vivek Kumar; Atul B Shinagare; Helmut G Rennke; Sandeep Ghai; Jochen H Lorch; Patrick A Ott; Osama E Rahma Journal: Oncologist Date: 2020-02-11